Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 220Neoplasms 192Carcinoma, Non-Small-Cell Lung 185Colorectal Neoplasms 129Prostatic Neoplasms 119Lung Neoplasms 107Neoplasm Metastasis 91Multiple Myeloma 89Ovarian Neoplasms 85Pancreatic Neoplasms 78Squamous Cell Carcinoma of Head and Neck 71Leukemia, Myeloid, Acute 70Melanoma 61Stomach Neoplasms 56Recurrence 51Endometrial Neoplasms 50Brain Neoplasms 46Lymphoma 45Carcinoma, Renal Cell 45Carcinoma, Hepatocellular 45Glioblastoma 44Urinary Bladder Neoplasms 43Triple Negative Breast Neoplasms 43Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Hematologic Neoplasms 40Esophageal Neoplasms 39Lymphoma, Large B-Cell, Diffuse 37Leukemia, Lymphocytic, Chronic, B-Cell 37Head and Neck Neoplasms 37Lymphoma, Non-Hodgkin 36

Interventions

darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × High-Risk Localized Prostate Cancer × 30 days × Clear all
NCT07450599 2026-05-13

CHINANEO

Bayer

Phase 2 Recruiting
250 enrolled
Genitourinary

High-Risk Localized Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡